As previously presented, both ABCG2 and ALDH were downregulated by ATO, which prompted us to investigate whether HCC cell resistance to conventional chemotherapy could be altered by ATO differentiation treatment. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.